CAS: 1057-07-4; [(5S,8R,9S,10S,13S,14S,17S)-10,13-Dimethyl-3-Oxo-1,2,4,5,6,7,8,9,11,12,14,15,16,17-Tetradecahydrocyclopenta[a]Phenanthren-17-Yl] Benzoate
该化合物是二氢苯酯酮(DHT)的合成衍生物,是一种强效激素,其特征是苯甲酸酯酯,它能增加其脂性,改变其药用动力特性.DHT本身是睾酮的代谢物,在培养男性特征和生殖功能方面发挥着关键作用.苯甲酸酯形式经常用于研究和治疗应用,特别是在激素替代疗法和与诱因效应有关的研究中.DHT Benzoate通常通过体内注射进行,允许体内持续释放和长时间活动.其化学结构包括一个带有苯甲酸酯的甲状腺骨,有助于其稳定性和有机溶液溶液溶液的溶液.与其他机器人一样,它可以影响各种生理过程,包括肌肉生长,发型和性能.但是,由于与诱导性活动有关的潜在副作用,例如丙烷,发型,发型变化和情绪变化,因此必须仔细监测其使用情况.
- 英文名称[(5S,8R,9S,10S,13S,14S,17S)-10,13-Dimethyl-3-Oxo-1,2,4,5,6,7,8,9,11,12,14,15,16,17-Tetradecahydrocyclopenta[a]Phenanthren-17-Yl] Benzoate
- 中文名称17-安息香酸雄甾醇酮
- IUPAC名称[(5S,8R,9S,10S,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl] benzoate
- 其它别名5a-Androstan-17b-ol-3-one benzoate
- CAS编号1057-07-4
- MFCD编号:MFCD00003666
- EINECS号:213-891-8
- FDA UNII编号:T74307G2D9
- 分子式:C26H34O3分子量:394.55
- 产品CID: 97944
- 产品分类分析化学 → 标准品 → 分析标准品
物理性质
MSDS等安全信息
欧盟法规
ECHA物质ECHA物质C&L通报REACH预注册上下游产品
CAS号98-88-4 苯甲酰氯 | CAS号894-65-5 Androst-1-en-17... | CAS号42723-62-6 5α-Androsten-(1... | CAS号2088-71-3 17-安息香酸雄烯醇酮 | CAS号1424-00-6 美睾酮 | CAS号65-06-5 1-睾酮合成工艺路线路线简述
📜(3B,5A,17B)-雄甾烷-3,17-二醇17-苯甲酸酯置于4-苯甲酰吡啶体系中,用 丙酮 用作溶剂,化学反应 46.0H,以76%的收率获得17-安息香酸雄甾醇酮
参考文献:Photoinduced Oxidation Of Secondary Alcohols Using 4-Benzoylpyridine As An Oxidant
标题:Photoinduced Oxidation Of Secondary Alcohols Using 4-Benzoylpyridine As An Oxidant
摘要:Photoinduced Oxidation Of Secondary Alcohols To Ketones Was Achieved By Utilizing An Equimolar Amount Of 4-Benzoylpyridine As An Oxidant. This Transformation Proceeds At Ambient Temperature And Exhibits High Compatibility With Polar Functionalities Including Benzoyl,Silyl,And Methoxymethyl Alcohol Protecting Groups As Well As Tosyloxy,Bromo,Sulfonyl,Carbamate,Ester,And Carboxylic Acid Units. The Present Oxidation Is Solely Promoted By The Action Of Organic Molecules Without The Aid Of Metallic Reagents.
Doi:10.1021/acs.Orglett.5B01550
海关参考信息
- 2905191000-3,3-二甲基丁-2-醇
2905222000-香茅醇 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-2018105546-A1
优先权日:2011-06-14
标题:Methods for Chemical Synthesis of Biologically Active Compounds Using Supramolecular Protective Groups and Novel Compounds Obtainable Thereby
专利号:US-2014243280-A1
优先权日:2011-06-14
标题:Methods for chemical synthesis of biologically active compounds using supramolecular protective groups and novel compounds obtainable Thereby
专利号:EP-2721046-A1
优先权日:2011-06-14
标题:Methods for chemical synthesis of biologically active compounds using supramolecular protective groups and novel compounds obtainable thereby
专利号:WO-2012173477-A1
优先权日:2011-06-14
标题 :Methods for chemical synthesis of biologically active compounds using supramolecular protective groups and novel compounds obtainable thereby
专利号:EP-2721046-B1
优先权日:2011-06-14
标题 :Methods for chemical synthesis of biologically active compounds using supramolecular protective groups and novel compounds obtainable thereby
发明人：HERRMANN ANDREAS; BASTIAN ANDREAS ALEXANDER; MARCOZZI ALESSIO
权利人:UNIV GRONINGEN
专利号:US-2025281509-A1
优先权日:2021-04-26
标 题 :Sequential hormone therapy to improve survival and enhance response to immune therapy in men with prostate cancer
发明人：DENMEADE SAMUEL R; ISAACS JOHN T; ANTONARAKIS EMMANUEL S; KACHHAP SUSHANT; MARKOWSKI MARK CHRISTOPHER
权利人:UNIV JOHNS HOPKINS
摘要:Disclosed are methods for treating men with castrate resistant prostate cancer with a sufficient dose of testosterone to achieve supraphysiologic serum levels of testosterone in sequence with androgen ablative treatment or androgen synthesis inhibitors for one or more cycles until evidence of radiographic progression, at which point the subject will receive immune checkpoint blockade therapy.
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
合成参考文献
摘要:S109 | PARCEDC | List of 7074 potential endocrine disrupting compounds (EDCs) by PARC T4.2 | DOI:10.5281/zenodo.10944198
📝 需求与反馈
尽可能描述清楚需求与问题信息
